Lucentis (ranibizumab): J2778 billing, dosing and coverage

Lucentis and the anti-VEGF family

9 HCPCS codes, one target: Lucentis is one of nine anti-VEGF products used for retinal disease, each priced and billed under its own code. They are not interchangeable, and most commercial policies write a preferred product into the claim before Lucentis is approved. Pricing comparison lives in Current Lucentis pricing.

What Lucentis is billed for

Lucentis carries five labeled indications, each with its own ICD-10 code: neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. Full dosing by indication is in Lucentis dosing by indication below, and the claim structure is in Lucentis billing reference.

19 of 27 ranibizumab payer policies in the corpus require a preferred agent first, usually repackaged bevacizumab (Avastin, off-label, J9035). BCBS AR instead designates Byooviz, Lucentis, Pavblu and Vabysmo as its preferred products: “Select products (e.g., Byooviz, Lucentis, Pavblu, Vabysmo) are preferred where there is an FDA approved indication for the biosimilar product and for all off-label uses of the reference product.” A non-preferred initial request draws an administrative denial: “Initial request must be for a preferred product. If initial request is not a preferred product, an administrative denial will be issued.”

Byooviz (Q5124)

Biogen / Samsung Bioepis · ranibizumab-nuna, the marketed ranibizumab biosimilar. This quarter Byooviz's ASP+6% payment limit, $249.49 per 0.1 mg, sits far above Lucentis's own $26.38 — the reference product is now priced below its biosimilar. Several payers, including BCBS AR, BCBS SC and Independence, list Byooviz among the preferred VEGF-inhibitor products; UHC does not — its preferred list is Avastin, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu and Vabysmo, and it typically excludes Byooviz from coverage as a non-preferred product.

Cimerli (Q5128)

Sandoz · ranibizumab-eqrn. Sandoz paused Cimerli's US commercialization in 2025, with no confirmed relaunch, so it stays in this table for the claims still arriving under Q5128, priced this quarter at $81.13 per 0.1 mg. Independence names Cimerli, alongside Lucentis and Byooviz, as a Level 2 preferred product; Wellmark and BCBS TN instead list it as non-preferred.

Lucentis dosing by indication

All five indications are adult; Lucentis has no pediatric indication. What changes by indication is the strength: 0.5 mg (0.05 mL of 10 mg/mL) for wet AMD, RVO and myopic CNV, 0.3 mg (0.05 mL of 6 mg/mL) for DME and diabetic retinopathy, each its own single-dose prefilled syringe or vial, injected once a month.

Schedule by indication

Wet AMD: 0.5 mg once a month (approximately 28 days). The label also describes two less-effective alternatives — 3 monthly doses then less-frequent dosing, or one dose every 3 months after 4 monthly doses — both intended for patients who cannot sustain monthly visits.

Macular edema following RVO: 0.5 mg once a month; the pivotal trials dosed monthly for 6 months, and patients not treated at month 6 lost visual acuity by month 7. Diabetic macular edema and diabetic retinopathy: 0.3 mg once a month, with no loading phase distinct from maintenance.

Myopic CNV: 0.5 mg once a month, initially for up to 3 months, with retreatment if needed. It is the only Lucentis indication with a labeled treatment course rather than an open-ended monthly schedule.

Contraindications and warnings

Lucentis carries no boxed warning. Contraindications are ocular or periocular infection and known hypersensitivity to ranibizumab or any excipient. The label warns of endophthalmitis and retinal detachment associated with intravitreal injections, increases in intraocular pressure before and after injection, a potential risk of arterial thromboembolic events, and — in patients with diabetic macular edema or diabetic retinopathy at baseline — a higher rate of fatal events observed in the pivotal trials; document the dose, the eye treated, and any post-injection symptoms in the chart at every visit.

Duration

Treatment is open-ended for wet AMD, RVO, DME and diabetic retinopathy: the label sets no stopping point, and the once-monthly schedule is the labeled one, so a payer's reauthorization runs on documented response — stable or improved visual acuity, OCT anatomy — rather than a calendar. Myopic CNV is the exception, a course of up to 3 monthly doses with retreatment as needed. Two eyes are two drug lines, each with its own eye modifier, and one 67028 line with modifier 50.

Need the billing units for a patient? Convert dose to J2778 billing units →

Lucentis billing reference

HCPCS

J2778: 0.1 mg per billing unit. The 0.5 mg dose (wet AMD, RVO, myopic CNV) bills as 5 units; the 0.3 mg dose (DME, diabetic retinopathy) bills as 3 units. Billing units are always whole numbers, and each strength is its own single-dose prefilled syringe or vial, so there is no partial-vial waste to report.

NDC

Four packages, each its own NDC across the two strengths: 50242-080-03 and 50242-080-88 for 0.5 mg, 50242-082-03 and 50242-082-88 for 0.3 mg. Pad to 11 digits with a leading zero in the appropriate segment for CMS-1500 Box 24A.

Administration: 67028 per eye, never 96372

The injection is the procedure, and it is reported per eye, because Lucentis has no administration code of its own. 96372 is wrong on every intravitreal claim.

A complete one-eye claim has two lines: J2778 with JZ and the eye modifier — 5 units at 0.5 mg or 3 units at 0.3 mg — and 67028 with the same eye modifier. Treating both eyes at the same visit adds a second drug line for the other eye, but the injection itself is still reported only once, as 67028-50, not as two full 67028 lines.

The Medically Unlikely Edit for J2778 is 10 units a day — two eyes at 5 units each, the 0.5 mg strength — which is the practical ceiling for a same-day bilateral claim, not a sign of an error.

Modifiers

JZ: required on every Lucentis dose line, since each strength is its own single-dose prefilled syringe or vial and the full contents are administered. RT / LT / 50: this modifier belongs on the drug line and on the 67028 line alike; a claim that carries it on only one of them is incomplete.

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Lucentis never has a JW scenario: both strengths are supplied as their own single-dose syringe or vial sized to the exact labeled dose, so nothing is ever discarded and JZ appears on every line.

Modifier 25: same-day E/M. Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into the procedure code.

TB: 340B drug pricing. Hospitals that acquire ranibizumab through 340B and bill Medicare report the TB modifier, the sole 340B identifier since CMS discontinued JG on January 1, 2025.

Claim form

CMS-1500 / 837P (physician office; POS 11) field map for a J2778 claim.

Calculate units & the eye modifier →

Lucentis coverage

• 21 of 27 commercial payer policy sets require prior authorization; 6 do not say clearly, so confirm those on the call
• 7 name a preferred ranibizumab product
• 27 payers carry a ranibizumab policy, covering 396 individual rules across covered indications, clinical prerequisites, quantity limits, contraindication exclusions, reauthorization, prior authorization, dosing, step therapy, preferred product, site of care, and combination rules
• 19 of 27 payers require another product first, most often repackaged bevacizumab (Avastin), though several instead name Byooviz or Cimerli, the ranibizumab biosimilars, as the preferred agent ahead of Lucentis itself
• 35 rules set a per-indication quantity limit, and 5 more set reauthorization terms that require continued-response documentation to keep the claim approved
• Because Lucentis, Byooviz and Cimerli are three separate HCPCS codes for three distinct ranibizumab products, confirm which code the policy actually names before treating; a payer's preferred-product rule may name Byooviz or Cimerli over Lucentis itself

ICD-10 codes by indication

Use the most specific code supported by chart documentation. Each labeled indication has its own code.

Step therapy: a preferred agent first

19 of 27 ranibizumab payer policies in the corpus require a preferred agent before Lucentis, almost always repackaged bevacizumab. BCBS MI: “Treatment with bevacizumab or a bevacizumab biosimilar has been ineffective, not tolerated or contraindicated.” Cigna requires that the patient has “previously tried repackaged bevacizumab; AND… [demonstrated] either inadequate efficacy or intolerability.”

Anthem runs its own VEGF Inhibitors Step Therapy program (CC-0072), whose commercial medical-benefit table lists Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis and Vabysmo as preferred agents. HMHS names bevacizumab and its biosimilars, Mvasi and Zirabev, as “the preferred products required for members initiating new therapy for neovascular (wet) age-related macular degeneration.”

Preferred over Lucentis itself

Some payers name a different ranibizumab product ahead of the reference drug. BCBS TN lists Lucentis and Cimerli only as “requested products”; the same-molecule preferred product is Byooviz. HMHS classifies Lucentis, along with Byooviz, Cimerli and Nufymco, as non-preferred, behind repackaged bevacizumab.

Quantity limits

Most caps restate the label's per-eye monthly dose in billable units. BCBS KS: “10 billable units every 28 days” for the 0.5 mg indications, “6 billable units every 28 days” for DME and DR; Capital Blue sets the same 10-unit and 6-unit caps, the latter “(Lucentis and Cimerli Only).” UHC caps annual volume instead of the monthly dose, allowing “no more than 12 doses per year per eye.”

Reauthorization

Coverage is not open-ended once approved. BCBS KS renews prior authorization “every 12 months (365 days)” generally, and “every 3 months (90 days)” for myopic CNV; UHC's authorization likewise runs “no more than 12 months.” Wellmark grants a further 12 months “for continued treatment… for members who have demonstrated a positive clinic[al response],” tying renewal to documented outcome rather than a fixed calendar.

Medicare has not issued a National Coverage Determination for intravitreal anti-VEGF drugs, so coverage is set instead by your MAC's Local Coverage Determination. See Lucentis coverage by payer for the rules each plan applies.

Check the patient's actual policy: See Lucentis coverage by payer →

Current Lucentis pricing

Medicare ASP+6%: $26.384 / 0.1 mg · $131.92 / 0.5 mg. For a one-eye claim at 0.5 mg, the drug line prices at 5 units × $26.384 = $131.92; add the $114.23 non-facility PFS allowance for 67028, and the claim totals $246.15 before the sequester, with a Medicare 20% coinsurance share of $49.23 ($26.38 on the drug line, $22.85 on 67028). At 0.3 mg (DME, DR), 3 units price at $79.15, the claim totals $193.38, and the 20% share is $38.68.

Both eyes at 0.5 mg price at $435.19 allowed ($87.04 at 20%), with 67028-50 replacing the two separate procedure lines. Commercial rates run higher: Aetna's all-state median is $66.86 per unit (0.1 mg), pricing the 5-unit dose at $334.30, and 37 of 37 payer files in the corpus carry a J2778 rate.

Sequestration reduces Medicare's 80% share by 2%. Commercial plans pay a contracted rate that differs by payer and state.

12 doses a year (0.5 mg per eye once a month (approximately every 28 days), the labeled schedule for wet AMD) at $246.15 per dose — drug plus 67028 administration — total $2,953.80 before the sequester. That is the full annual drug-plus-administration cost for a patient staying on schedule, before benefits or assistance.

Look up commercial reimbursement →

Patient cost

The patient's actual responsibility depends on: payer allowed rate · remaining Part B deductible ($283 in 2026) · benefits · − assistance · = patient responsibility. At 20% coinsurance with the deductible already met, a Medicare patient's share of a one-eye Lucentis visit at 0.5 mg is $49.23: $26.38 on the drug line, $22.85 on the 67028 procedure line. Both eyes at the same visit run $87.04: $26.38 per eye on the drug lines plus $34.27 on the 67028-50 line.

At the 0.3 mg strength (DME, diabetic retinopathy), the one-eye share is $38.68: $15.83 on the drug line and $22.85 on 67028.

Calculate a Lucentis patient estimate →

Copay & financial assistance

Two Genentech programs cover Lucentis: the Genentech Ophthalmology Co-pay Program brings a commercial patient's drug cost to $0, up to $15,000 a year, and adds up to $1,000 a year toward the 67028 injection administration copay; the Genentech Patient Foundation provides the drug free to qualifying uninsured patients with household income under $150,000. A patient on Medicare, Medicaid or another government plan qualifies for neither. Check current open/closed status before pointing a patient to either, since status changes without notice.

Nine foundation funds are on file for Lucentis. The Assistance Fund's Macular Degeneration fund is on file; check each fund's current status on the funds list. The other eight are HealthWell Foundation's Macular Degeneration fund (up to $4,000 a year), Good Days' two retinal-disease funds, and five TotalAssist eye funds; check each fund's current status on the funds list. See current Lucentis assistance programs →

See current Lucentis assistance programs →

Common Lucentis denials & fixes